ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9871del (p.Ser3291fs) (rs886040854)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000256542 SCV000324797 pathogenic Breast-ovarian cancer, familial 2 2016-10-18 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000256542 SCV000328173 pathogenic Breast-ovarian cancer, familial 2 2015-10-02 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000755865 SCV000883492 pathogenic not provided 2018-01-08 criteria provided, single submitter clinical testing The BRCA2 c.9871delT; p.Ser3291fs variant (rs886040854), to our knowledge, has not been previously reported in the literature. However, this variant is classified as pathogenic by two review panels in ClinVar (Variation ID: 267176). It is absent from general population databases (Exome Variant Server, Genome Aggregation Database, 1000 Genomes Project), indicating it is not a common polymorphism. This variant causes a frameshift starting at codon 3291 and an early termination codon at residue 3312, which results in 21 novel amino acids and a loss of the final 128 coding amino acids of BRCA2. This region of the carboxyl terminus is important for RAD51 binding; Ser3291 specifically, serves as a molecular switch for the regulation of homologous recombination, and alterations at Ser3291 are reported to abrogate RAD51 binding (Chalermrujinanant 2016, Davies 2007, Esashi 2007, Guidugli 2014, Tram 2013). In vitro functional studies of a nearby truncation, p.Tyr3308Ter, have also demonstrated a deleterious effect on BRCA2 function including sensitivity to DNA damaging agents, homologous recombination, and RAD51-mediated DNA repair (Hucl 2008, Kuznetsov 2008, Ray Chaudhuri 2016). The p.Tyr3308Ter variant is also classified as pathogenic by multiple laboratories in ClinVar (Variation IDs: 267177, 52916). It is well established that the downstream nonsense variant p.Lys3326Ter (Variation ID: 38266) is benign and this has caused difficulties in reaching consensus on the clinical significance of other nonsense and frameshift variants towards the end of this final exon. However, nonsense and frameshift variants occurring in the RAD51 binding domain or further upstream are by consensus considered deleterious with the exception of one (c.9699_9702del, Variation ID: 38260), which may have more variable penetrance (Rosenthal 2015). Although the pathogenicity of truncating variants in the last coding exon of BRCA2 is variable, the published data indicates that amino acid residues p.3260_p.3305 contribute a unique role to RAD51 binding and, thus, are important for proper BRCA2 function. Based on the functional data regarding Ser3291, the p.Ser3291fs variant is considered pathogenic, although it is not possible to predict its penetrance. REFERENCES Chalermrujinanant C et al. Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation. Oncogene. 2016 Jun 2;35(22):2815-23. Davies OR et al. Interaction with the BRCA2 C terminus protects RAD51-DNA filaments from disassembly by BRC repeats. Nat Struct Mol Biol. 2007 Jun;14(6):475-83. Esashi F et al. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat Struct Mol Biol. 2007 Jun;14(6):468-74. Guidugli L et al. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat. 2014 Feb;35(2):151-64. Hucl T et al. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res. 2008 Jul 1;68(13):5023-30. Kuznetsov SG et al. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med. 2008 Aug;14(8):875-81. Ray Chaudhuri A et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016 Jul 21;535(7612):382-7. Rosenthal ET et al. Exceptions to the rule: case studies in the prediction of pathogenicity for genetic variants in hereditary cancer genes. Clin Genet. 2015 Dec;88(6):533-41. Tram E et al. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2. PLoS One. 2013 May 21;8(5):e62468.
Color RCV000776118 SCV000910992 pathogenic Hereditary cancer-predisposing syndrome 2018-04-10 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.